Docusign Inc vs UiPath Inc — how do they compare? Docusign Inc trades at $71.49 (market cap $13.35B), while UiPath Inc trades at $13.34 (market cap $6.91B). The key difference: Docusign Inc is the larger of the two by market cap, and Docusign Inc is trading nearer its 52-week high, UiPath Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Docusign Inc for 71 Days and UiPath Inc for 139 Days on average.
| DOCU | PATH | |
|---|---|---|
Market Cap | $13.35B | $6.91B |
Volume | 3,158,858 | 34,321,250 |
Sector | Technology | Technology |
52-Week High | $73.14 | $19.29 |
52-Week Low | $41.75 | $9.38 |
Typical Hold Time | 71 Days | 139 Days |
Enterprise Value | $12.76B | $5.70B |
Signals from Pluang's Aura AI — not financial advice
DocuSign (DOCU) trades at $68.9, up 1.0% on the day, with a bullish technical outlook supported by moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $1.16 surpassing the $1.09 forecast. Revenue growth remains solid, reaching $2.98B in 2025, while profitability has improved significantly, with net income margin at 9.82%. Recent news highlights strong momentum, including a 50.8% stock surge over three months and leadership in IDC's integrated signing workflow software assessment (IDC MarketScape, August 2026).
The outlook for DOCU is cautiously optimistic, driven by AI-powered Intelligent Agreement Management adoption and operating leverage. However, risks include saturation in the e-signature market, insider selling activity, and a high P/E ratio of 42.01. Analyst consensus is mixed, with a Hold rating predominating (64.29%) and a price target of $68.75, slightly below the current price. Investors should weigh strong cash flow generation against valuation concerns and competitive pressures.
UiPath (PATH) trades at $13.07, down 0.23% on the day, amid a bearish technical signal and mixed earnings history. The company shows improving fundamentals with revenue growing from $1.43B in 2025 to a projected $1.7B in 2026, while net income is expected to turn positive. Recent news highlights AI partnerships and product innovations, but the stock faces headwinds from cautious analyst sentiment and technical resistance.
The outlook for PATH is cautiously optimistic, with strong revenue growth and a path to profitability offering upside potential, but risks include execution challenges and competitive pressures. The consensus price target of $15.13 suggests moderate upside from current levels, though investor sentiment remains divided.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →